Last update 20 Jun 2024
Zeteletinib
Last update 20 Jun 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Zeteletinib Adipate, BOS 172738, BOS-172738 + [1] |
Target |
Mechanism RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Structure
Molecular FormulaC25H23F3N4O4 |
InChIKeyKOLQINCWMXQEOF-UHFFFAOYSA-N |
CAS Registry2216753-97-6 |
Related
1
Clinical Trials associated with ZeteletinibA Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)
100 Clinical Results associated with Zeteletinib
Login to view more data
100 Translational Medicine associated with Zeteletinib
Login to view more data
100 Patents (Medical) associated with Zeteletinib
Login to view more data
100 Deals associated with Zeteletinib
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | US | Boston Pharmaceuticals, Inc.Startup | 12 Dec 2018 |
| Advanced Malignant Solid Neoplasm | Phase 1 | BE | Boston Pharmaceuticals, Inc.Startup | 12 Dec 2018 |
| Advanced Malignant Solid Neoplasm | Phase 1 | FR | Boston Pharmaceuticals, Inc.Startup | 12 Dec 2018 |
| Advanced Malignant Solid Neoplasm | Phase 1 | HK | Boston Pharmaceuticals, Inc.Startup | 12 Dec 2018 |
| Advanced Malignant Solid Neoplasm | Phase 1 | KR | Boston Pharmaceuticals, Inc.Startup | 12 Dec 2018 |
| Advanced Malignant Solid Neoplasm | Phase 1 | ES | Boston Pharmaceuticals, Inc.Startup | 12 Dec 2018 |
| Advanced Malignant Solid Neoplasm | Phase 1 | TW | Boston Pharmaceuticals, Inc.Startup | 12 Dec 2018 |
| Non-Small Cell Lung Cancer | Phase 1 | US | Boston Pharmaceuticals, Inc.Startup | 12 Dec 2018 |
| Non-Small Cell Lung Cancer | Phase 1 | BE | Boston Pharmaceuticals, Inc.Startup | 12 Dec 2018 |
| Non-Small Cell Lung Cancer | Phase 1 | FR | Boston Pharmaceuticals, Inc.Startup | 12 Dec 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT03780517 (ASCO2021) Manual  | Phase 1 | RET mutation Solid Tumors RET Mutation | 67 | tqqspiyesv(thqiozfhce) = The most TEAEs classified as grade ≤2 and deemed unrelated to drug. The most common TEAEs were creatinine phosphokinase (CPK) increase (54%), dyspnea (34%), facial edema, aspartate aminotransferase elevation, anemia (25% each), neutropenia, diarrhea (22% each), fatigue (21%), and constipation (20%). cvgtawrjum (skpmczckgb ) | Positive | 20 May 2021 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free